TY - JOUR
T1 - Lipid trait variants and the risk of non-hodgkin lymphoma subtypes
T2 - a mendelian randomization study
AU - Kleinstern, Geffen
AU - Camp, Nicola J.
AU - Berndt, Sonja I.
AU - Birmann, Brenda M.
AU - Nieters, Alexandra
AU - Bracci, Paige M.
AU - McKay, James D.
AU - Ghesquieres, Herve
AU - Lan, Qing
AU - Hjalgrim, Henrik
AU - Benavente, Yolanda
AU - Monnereau, Alain
AU - Wang, Sophia S.
AU - Zhang, Yawei
AU - Purdue, Mark P.
AU - Zeleniuch-Jacquotte, Anne
AU - Giles, Graham G.
AU - Vermeulen, Roel
AU - Cocco, Pierluigi
AU - Albanes, Demetrius
AU - Teras, Lauren R.
AU - Brooks-Wilson, Angela R.
AU - Vajdic, Claire M.
AU - Kane, Eleanor
AU - Caporaso, Neil E.
AU - Smedby, Karin E.
AU - Salles, Gilles
AU - Vijai, Joseph
AU - Chanock, Stephen J.
AU - Skibola, Christine F.
AU - Rothman, Nathaniel
AU - Slager, Susan L.
AU - Cerhan, James R.
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/5
Y1 - 2020/5
N2 - Background: Lipid traits have been inconsistently linked to risk of non-Hodgkin lymphoma (NHL). We examined the association of genetically predicted lipid traits with risk of diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) using Mendelian randomization (MR) analysis. Methods: Genome-wide association study data from the InterLymph Consortium were available for 2,661 DLBCLs, 2,179 CLLs, 2,142 FLs, 824 MZLs, and 6,221 controls. SNPs associated (P < 5 108) with high-density lipoprotein (HDL, n ¼ 164), low-density lipoprotein (LDL, n ¼ 137), total cholesterol (TC, n ¼ 161), and triglycerides (TG, n ¼ 123) were used as instrumental variables (IV), explaining 14.6%, 27.7%, 16.8%, and 12.8% of phenotypic variation, respectively. Associations between each lipid trait and NHL subtype were calculated using the MR inverse variance–weighted method, estimating odds ratios (OR) per standard deviation and 95% confidence intervals (CI). Results: HDL was positively associated with DLBCL (OR ¼ 1.14; 95% CI, 1.00–1.30) and MZL (OR ¼ 1.09; 95% CI, 1.01–1.18), while TG was inversely associated with MZL risk (OR ¼ 0.90; 95% CI, 0.83–0.99), all at nominal significance (P < 0.05). A positive trend was observed for HDL with FL risk (OR ¼ 1.08; 95% CI, 0.99–1.19; P ¼ 0.087). No associations were noteworthy after adjusting for multiple testing. Conclusions: We did not find evidence of a clear or strong association of these lipid traits with the most common NHL subtypes. While these IVs have been previously linked to other cancers, our findings do not support any causal associations with these NHL subtypes. Impact: Our results suggest that prior reported inverse associations of lipid traits are not likely to be causal and could represent reverse causality or confounding.
AB - Background: Lipid traits have been inconsistently linked to risk of non-Hodgkin lymphoma (NHL). We examined the association of genetically predicted lipid traits with risk of diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) using Mendelian randomization (MR) analysis. Methods: Genome-wide association study data from the InterLymph Consortium were available for 2,661 DLBCLs, 2,179 CLLs, 2,142 FLs, 824 MZLs, and 6,221 controls. SNPs associated (P < 5 108) with high-density lipoprotein (HDL, n ¼ 164), low-density lipoprotein (LDL, n ¼ 137), total cholesterol (TC, n ¼ 161), and triglycerides (TG, n ¼ 123) were used as instrumental variables (IV), explaining 14.6%, 27.7%, 16.8%, and 12.8% of phenotypic variation, respectively. Associations between each lipid trait and NHL subtype were calculated using the MR inverse variance–weighted method, estimating odds ratios (OR) per standard deviation and 95% confidence intervals (CI). Results: HDL was positively associated with DLBCL (OR ¼ 1.14; 95% CI, 1.00–1.30) and MZL (OR ¼ 1.09; 95% CI, 1.01–1.18), while TG was inversely associated with MZL risk (OR ¼ 0.90; 95% CI, 0.83–0.99), all at nominal significance (P < 0.05). A positive trend was observed for HDL with FL risk (OR ¼ 1.08; 95% CI, 0.99–1.19; P ¼ 0.087). No associations were noteworthy after adjusting for multiple testing. Conclusions: We did not find evidence of a clear or strong association of these lipid traits with the most common NHL subtypes. While these IVs have been previously linked to other cancers, our findings do not support any causal associations with these NHL subtypes. Impact: Our results suggest that prior reported inverse associations of lipid traits are not likely to be causal and could represent reverse causality or confounding.
KW - Causality
KW - Cholesterol/blood
KW - Genetic Predisposition to Disease
KW - Genome-Wide Association Study
KW - Humans
KW - Leukemia, Lymphocytic, Chronic, B-Cell/blood
KW - Lipid Metabolism/genetics
KW - Lipoproteins, HDL/blood
KW - Lipoproteins, LDL/blood
KW - Lymphoma, B-Cell, Marginal Zone/blood
KW - Lymphoma, Follicular/blood
KW - Lymphoma, Large B-Cell, Diffuse/blood
KW - Mendelian Randomization Analysis
KW - Odds Ratio
KW - Polymorphism, Single Nucleotide
KW - Quantitative Trait Loci
KW - Risk Factors
KW - Triglycerides/blood
UR - http://www.scopus.com/inward/record.url?scp=85084961329&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-19-0803
DO - 10.1158/1055-9965.EPI-19-0803
M3 - Article
C2 - 32108027
AN - SCOPUS:85084961329
SN - 1055-9965
VL - 29
SP - 1074
EP - 1078
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -